3. Segment Information and Concentrations

6 Months Ended

Dec. 31, 2018

Segment Reporting [Abstract]

Segment Information and Concentrations

The Company views its operations as three segments: the manufacture and marketing of standard benchtop laboratory equipment for research in university, hospital and industrial laboratories sold primarily through laboratory equipment distributors and laboratory and pharmacy balances and scales (“Benchtop Laboratory Equipment Operations”), the manufacture and marketing of custom-made catalyst research instruments for universities, government laboratories, and chemical and petrochemical companies sold on a direct basis (“Catalyst Research Instruments Operations”) and the design and marketing of bioprocessing systems and products and related royalty income (“Bioprocessing Systems”).

Segment information is reported as follows:

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate And Other		Consolidated
Three Months Ended December 31, 2018:
Revenues	$	1,803,100	$	227,200		$	132,900	$	-	$	2,163,200
Foreign Sales		743,600		222,900			-		-		966,500
Income (Loss) From Operations		148,600		(48,300	)		55,700		-		156,000
Assets		4,762,000		1,376,100			727,300		693,300		7,558,700
Long-Lived Asset Expenditures		10,800		1,200			-		-		12,000
Depreciation and Amortization		66,400		200			9,400		-		76,000

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate And Other		Consolidated
Three Months Ended December 31, 2017:
Revenues	$	1,686,200	$	153,500		$	52,700		$	-	$	1,892,400
Foreign Sales		815,300		2,600			-			-		817,900
Income (Loss) From Operations		122,000		(103,400	)		(8,300	)		-		10,300
Assets		4,085,800		1,613,200			467,900			803,300		6,970,200
Long-Lived Asset Expenditures		33,000		1,900			2,500			-		37,400
Depreciation and Amortization		67,000		700			9,300			-		77,000

Approximately 51% and 53% of total benchtop laboratory equipment sales (42% and 48% of total revenues) for the three month periods ended December 31, 2018 and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 25% and 21% of total benchtop laboratory equipment sales (21% and 19% of total revenues) were derived from the Torbal Scales Division for the three months ended December 31, 2018 and 2017, respectively.

For the three months ended December 31, 2018 and 2017, respectively, three customers accounted for approximately 21% and 22% of net sales of the Benchtop Laboratory Equipment Operations (18% and 20% of the Company’s total revenues). Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to two and one customer during the three months ended December 31, 2018 and 2017, accounted for approximately 96% and 74% of the Catalyst Research Instrument Operations’ revenues and 10% and 7% of the Company’s total revenues, respectively.

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems		Corporate And Other		Consolidated
Six Months Ended December 31, 2018:
Revenues	$	3,495,100	$	444,600		$	262,100	$	-	$	4,201,800
Foreign Sales		1,379,300		365,200			-		-		1,744,500
Income (Loss) From Operations		324,200		(111,300	)		118,900		-		331,800
Assets		4,762,000		1,376,100			727,300		693,300		7,558,700
Long-Lived Asset Expenditures		13,000		1,200			-		-		14,200
Depreciation and Amortization		132,700		400			18,800		-		151,900

	Benchtop Laboratory Equipment		Catalyst Research Instruments			Bioprocessing Systems			Corporate And Other		Consolidated
Six Months Ended December 31, 2017:
Revenues	$	2,885,600	$	182,300		$	105,400		$	-	$	3,173,300
Foreign Sales		1,317,600		9,000			-			-		1,326,600
Income (Loss) From Operations		28,100		(287,500	)		(37,100	)		-		(296,500	)
Assets		4,085,800		1,613,200			467,900			803,300		6,970,200
Long-Lived Asset Expenditures		65,200		1,900			2,500			-		69,600
Depreciation and Amortization		131,900		3,500			18,700			-		154,100

Approximately 50% total benchtop laboratory equipment sales (41% and 46% of total revenues) for both six month periods ended December 31, 2018 and 2017, respectively, were derived from the Company’s main product, the Vortex-Genie 2 mixer, excluding accessories.

Approximately 25% and 23% of total benchtop laboratory equipment sales (21% of total revenues) were derived from the Torbal Scales Division for both the six months ended December 31, 2018 and 2017, respectively. For the six months ended December 31, 2018 and 2017, respectively, three customers accountedy for approximately 22% of net sales of the Benchtop Laboratory Equipment Operations for both six month periods ended December 31, 2018 and 2017 (18% and 20% of the Company’s total revenues), respectively.

Sales of catalyst research instruments generally comprise a few very large orders averaging approximately $50,000 per order to a limited number of customers, who differ from order to order. Sales to five and one customer during the six months ended December 31, 2018 and 2017, accounted for approximately 90% and 64% of the Catalyst Research Instrument Operations’ revenues and 10% and 4% of the Company’s total revenues, respectively.